- Korea’s largest biopharmaceutical exhibition “BIX 2025” held from October 15 to 17

- Operated an independent exhibition booth for the fourth consecutive year

▲ Exhibition booth of PCMO at BIX 2025

PCMO (Director: Cho Min, hereinafter referred to as the “Center”) announced on the 21st that it participated in the BioPlus-Interphex Korea 2025 (BIX 2025), held from October 15 to 17 at COEX in Seoul, where it held business meetings with domestic and international companies specializing in mRNA-related materials, parts, and equipment to strengthen technological cooperation.

At BIX 2025, the largest pharmaceutical and biotechnology exhibition in Korea, the Center discussed collaboration opportunities with global drug development companies and showcased its capabilities and role as a public CDMO (Contract Development and Manufacturing Organization). Established in 2017, the Center has completed the construction of its new mRNA manufacturing facility this year, marking a major step toward expanding into new business areas.

Building on its experience as a public CDMO institution, the Center is now promoting projects focused on localizing key mRNA/LNP-based materials, supporting the establishment of manufacturing process demonstration infrastructure, and providing end-to-end R&D support including GMP certification and technical consulting.

A Center representative stated, “With the dedicated mRNA/LNP GMP facility nearing completion, securing a stable supply chain through the localization of raw materials and core technologies has become more important than ever,” adding, “Through participation in BIX 2025, we were able to expand practical technology cooperation networks with both domestic and international component and equipment companies.”

▲ From left: PCMO main plant, mRNA building, and training center

Meanwhile, in July 2025, the Center opened an advanced training and production complex equipped for large-scale GMP operations—the largest of its kind in the Gwangju-Jeonnam region. Supported by the Ministry of Trade, Industry and Energy, Jeollanam-do Province, and Hwasun County, the Center is actively nurturing skilled professionals in vaccine and biopharmaceutical production through the Vaccine Industry Professional Workforce Development Program.

During the exhibition, the Center also received a high volume of inquiries not only about its CDMO services but also about its educational programs, reaffirming strong industry interest. The Center continues to solidify its position as both a public CDMO hub and a biopharmaceutical education institute, with growing expectations for its future development.